English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Genotype‐based algorithms that include  VKORC1  and  CYP2C9  genotypes are less predictive of warfarin dose variability in Africans as opposed to Europeans. Polymorphisms in  GGCX, FPGS , or  STX1B  are associated with warfarin dose requirements in African‐Americans. We sought to determine if they influenced warfarin dose in European‐Americans, and another African population, specifically Egyptians. We genotyped 529 adults ( n  = 325 European‐Americans, 204 Egyptians) on a stable warfarin dose for  GGCX  rs12714145 and rs10654848,  FPGS  rs7856096, and  STX1B  rs4889606. Rs12714145, rs10654848, and rs7856096 were not associated with warfarin dose, whereas  STX1B  rs4889606 was a significant determinant in univariate analysis ( P  < 0.0001) in both cohorts. However,  STX1B  rs4889606 was in high linkage disequilibrium with  VKORC1 ‐1639 G>A, and was no longer significant after including  VKORC1 ‐1639 G>A in the regression model. Based on these data, the polymorphisms do not appear to influence, in a clinically important way, warfarin dose requirements in European‐Americans and Egyptians.

Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European‐Americans and Egyptians